Macrophage-specific MerTK is also a therapeutic target of interest, with improved survival rates seen with inhibitory mAbs combined with RT-anti-PD1 in lung adenocarcinomas, and tumour regression when combined with RT and TGFβ blockade in poorly immunogenic tumour models [56, 82]. This evidence concerns the gene MERTK and neoplasm.